- Home
- NSTS vs TLPH Comparison
NSTS vs TLPH Comparison
Compare NSTS & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NSTS | TLPH |
|---|---|---|
| Founded | 1921 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.7M | 64.7M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | NSTS | TLPH |
|---|---|---|
| Price | $11.86 | $1.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 6.4K | ★ 330.7K |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,762,000.00 | $28,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $14,267.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 57.78 | N/A |
| 52 Week Low | $10.72 | $0.38 |
| 52 Week High | $13.32 | $1.57 |
Technical Indicators
Market Signals| Indicator | NSTS | TLPH |
|---|---|---|
| Relative Strength Index (RSI) | 68.20 | 39.86 |
| Support Level | $11.70 | $1.20 |
| Resistance Level | $11.89 | $1.25 |
| Average True Range (ATR) | 0.14 | 0.09 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 84.94 | 10.00 |
Price Performance
Historical ComparisonAbout NSTS NSTS Bancorp Inc.
NSTS Bancorp Inc is a savings and loan holding company regulated Federal Reserve Board. The company was formed to serve as the North Shore Trust and Savings stock holding company. The Bank is a wholly-owned subsidiary of the company and operates as a traditional savings institution focused on serving the banking needs of customers in market area of Lake County, Illinois and adjacent communities.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.